Pfizer (PFE) Revenue (2009 - 2026)

Pfizer (PFE) has 18 years of Revenue data on file, last reported at $2.3 billion in Q1 2026.

• Quarterly Revenue rose 10.7% year-over-year to $2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.5 billion (down 20.35% YoY) and the FY2025 annual result came in at $62.6 billion, up 646.05% from the prior year.
• Revenue slipped to $2.3 billion in Q1 2026 per PFE's latest filing, from $17.6 billion in the prior quarter.
• Across five years, Revenue topped out at $27.7 billion in Q3 2022 and bottomed at $442.0 million in Q3 2024.
• The 5-year median for Revenue is $3.5 billion (2023), against an average of $9.2 billion.
• The widest annual swing landed in 2023, when Revenue slumped 92.73%; it then soared 419.91% in 2025.
• Tracing PFE's Revenue over 5 years: stood at $3.3 billion in 2022, then rose by 5.31% to $3.4 billion in 2023, then sank by 87.13% to $442.0 million in 2024, then surged by 3872.17% to $17.6 billion in 2025, then sank by 86.68% to $2.3 billion in 2026.
• Per Business Quant, the three latest PFE Revenue figures stand at $2.3 billion (Q1 2026), $17.6 billion (Q4 2025), and $2.3 billion (Q3 2025).

Peer Comparison